Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Planned maintenance
A system upgrade is planned for 10/12-2024, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Methylation in MAD1L1 is associated with the severity of suicide attempt and phenotypes of depression
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Functional Pharmacology and neuroscience.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Functional Pharmacology and neuroscience.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Functional Pharmacology and neuroscience.
Umeå Univ, Dept Clin Sci Psychiat, Umeå, Sweden.;Karolinska Inst, Dept Womens & Childrens Hlth Neuropediat, Stockholm, Sweden..
Show others and affiliations
2023 (English)In: Clinical Epigenetics, E-ISSN 1868-7083, Vol. 15, article id 1Article in journal (Refereed) Published
Abstract [en]

Depression is a multifactorial disorder representing a significant public health burden. Previous studies have linked multiple single nucleotide polymorphisms with depressive phenotypes and suicidal behavior. MAD1L1 is a mitosis metaphase checkpoint protein that has been linked to depression in GWAS. Using a longitudinal EWAS approach in an adolescent cohort at two time points (n = 216 and n = 154), we identified differentially methylated sites that were associated with depression-related genetic variants in MAD1L1. Three methylation loci (cg02825527, cg18302629, and cg19624444) were consistently hypomethylated in the minor allele carriers, being cross-dependent on several SNPs. We further investigated whether DNA methylation at these CpGs is associated with depressive psychiatric phenotypes in independent cohorts. The first site (cg02825527) was hypomethylated in blood (exp(beta) = 84.521, p value similar to 0.003) in participants with severe suicide attempts (n = 88). The same locus showed increased methylation in glial cells (exp(beta) = 0.041, p value similar to 0.004) in the validation cohort, involving 29 depressed patients and 29 controls, and showed a trend for association with suicide (n = 40, p value similar to 0.089) and trend for association with depression treatment (n = 377, p value similar to 0.075). The second CpG (cg18302629) was significantly hypomethylated in depressed participants (exp(beta) = 56.374, p value similar to 0.023) in glial cells, but did not show associations in the discovery cohorts. The last methylation site (cg19624444) was hypomethylated in the whole blood of severe suicide attempters; however, this association was at the borderline for statistical significance (p value similar to 0.061). This locus, however, showed a strong association with depression treatment in the validation cohort (exp(beta) = 2.237, p value similar to 0.003) with 377 participants. The direction of associations between psychiatric phenotypes appeared to be different in the whole blood in comparison with brain samples for cg02825527 and cg19624444. The association analysis between methylation at cg18302629 and cg19624444 and MAD1L1 transcript levels in CD14+ cells shows a potential link between methylation at these CpGs and MAD1L1 expression. This study suggests evidence that methylation at MAD1L1 is important for psychiatric health as supported by several independent cohorts.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2023. Vol. 15, article id 1
Keywords [en]
DNA methylation, Depression, Suicide
National Category
Psychiatry Medical Genetics
Identifiers
URN: urn:nbn:se:uu:diva-495863DOI: 10.1186/s13148-022-01394-5ISI: 000908834800002PubMedID: 36600305OAI: oai:DiVA.org:uu-495863DiVA, id: diva2:1735407
Funder
Swedish Research Council, K2009-61P-21304-04-4Uppsala UniversityThe Swedish Brain FoundationSwedish Research Council, K2009-61X-21305-01-1Region Västerbotten, VLL-582221Region Stockholm, SLL-20150269Available from: 2023-02-08 Created: 2023-02-08 Last updated: 2024-10-10Bibliographically approved
In thesis
1. Biomarkers for depression: genetic, epigenetic, and expression evidence
Open this publication in new window or tab >>Biomarkers for depression: genetic, epigenetic, and expression evidence
2024 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Depression is a very prevalent disorder affecting between 2 to 21% of the world population. This thesis extends the knowledge on the biological aspects of depression, aiming to identify and validate markers of genetic, epigenetic, and gene expression origin.

In Study I, the main focus was depression-related gene MAD1L1 that was previously linked to depression by SNPs and frequently mentioned as a stress-related marker. We identified that depression-related SNPs in MAD1L1 affect DNA methylation levels at cg02825527, cg18302629, and cg19624444 that were associated with depressive phenotypes in independent cohorts.

In Study II, we investigated whether GWAS catalog depression SNPs located in Olink-detectable genes could be replicated in a UKBiobank cohort and whether these associations are supported by DNA methylation and transcriptome. We validated eight depression SNPs and found very weak evidence that TNXB may be related to depression.

Study III was based on comparison of different depression -OMIC layers, including genetics, DNA methylation, and transcriptome. We explored how the identified genes from different -OMICs overlap, are functionally related and if they could show patterns in drugs and clinical trials. Only three genes were supported by evidence at all three -OMIC levels and included: FOXP1, VPS41, and AKTIP. Different -OMIC levels showed involvement of multiple systems in depression.

In Study IV, we used the Neuro Exploratory panel (Olink) to identify depression proteomic changes in blood. We took antidepressant intake into the account and validated associations in the independent datasets. We identified several proteins that showed nominally different levels between depression risk groups in the adolescent cohort. Validation of identified markers yielded that only PPP3R1 was also differentially expressed in prefrontal cortex and whole blood in the independent open-access cohorts with matching association directions.

In Study V, we used the entire blood DNA methylation as a depression marker. We investigated stability of DNA-methylation in eight independent datasets with meta-analysis and compared common machine learning and deep learning strategies for the depression detection purposes. We found 1987 CpG sites related to depression in both mega- and meta-analysis at the nominal level. Random forest classifiers achieved the best performance in identifying depression based on DNA methylation data in blood (AUC 0.73 and 0.76) in CV and hold-out tests respectively on the batch-level processed data.

Overall, the thesis supports multiple depression genetic, epigenetic, and expression markers. However, identified individual and systemic depression changes show high variability, which is in agreement with previous studies and observations.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2024. p. 98
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2093
Keywords
Depression, Biomarkers, Epigenetics, DNA methylation, Proteomics, Transcriptomics, Genetics, Machine learning
National Category
Bioinformatics (Computational Biology) Psychiatry Neurosciences
Research subject
Psychiatry; Bioinformatics
Identifiers
urn:nbn:se:uu:diva-540129 (URN)978-91-513-2270-4 (ISBN)
Public defence
2024-12-04, room A1:111a, Uppsala biomedicinska centrum (BMC), Husargatan 3, Uppsala, 13:00 (English)
Opponent
Supervisors
Available from: 2024-11-13 Created: 2024-10-10 Last updated: 2024-11-13

Open Access in DiVA

fulltext(3761 kB)202 downloads
File information
File name FULLTEXT01.pdfFile size 3761 kBChecksum SHA-512
2c99c95f94e642d010daaf9af0d99c07feb9f4fd4607c951352624125013799c285553d05339713d3459a9d00d4aae45f6ca86165c2cc2364083bc0f758f5f2f
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Sokolov, Aleksandr V.Schiöth, Helgi B.

Search in DiVA

By author/editor
Sokolov, Aleksandr V.Schiöth, Helgi B.
By organisation
Functional Pharmacology and neuroscience
In the same journal
Clinical Epigenetics
PsychiatryMedical Genetics

Search outside of DiVA

GoogleGoogle Scholar
Total: 202 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 110 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf